Inicio
Proyectos y Estudios
Estudio prospectivo, aleatorizado, comparativo, sin enmascaramiento, multicéntrico, para evaluar la eficacia, seguridad y los resultados percibidos por los pacientes de la terapia con péptidos marcados con radionúclidos (PRRT) (lutecio [177Lu] edotreotida) en comparación con el tratamiento de referencia en pacientes con tumores neuroendocrinos de origen gastroentérico o pancreático (TNE-GEP) bien diferenciado, agresivo, de grado 2 o de grado 3 y que exprese receptores de la somatostatina (SSTR+) (COMPOSE).

Estudio prospectivo, aleatorizado, comparativo, sin enmascaramiento, multicéntrico, para evaluar la eficacia, seguridad y los resultados percibidos por los pacientes de la terapia con péptidos marcados con radionúclidos (PRRT) (lutecio [177Lu] edotreotida) en comparación con el tratamiento de referencia en pacientes con tumores neuroendocrinos de origen gastroentérico o pancreático (TNE-GEP) bien diferenciado, agresivo, de grado 2 o de grado 3 y que exprese receptores de la somatostatina (SSTR+) (COMPOSE).

Datos básicos

Código:: DP-1111-02CT
Protocolo:: DP-1111-02CT
EUDRACT:: 2021-001086-20
NCT:
Centro:: HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:: 2022
Año de finalización:: 2025

ENSAYO CLÍNICO

Objetivos del proyecto

Objetivo Principal: Demostrar la eficacia de la terapia con péptidos marcados con radionúclidos (PRRT) (lutecio [177Lu] edotreotida) en el tratamiento de los TNE-GEP SSTR+ agresivos, de grado 2 (G2; Ki67 entre 15 y 20, ambos inclusive) y de grado 3 (G3; Ki67 por encima de 20 y hasta 55, ambos inclusive) en comparación con el tratamiento de referencia (seleccionado por el investigador [de la lista de tratamientos comparativos que se incluye en el protocolo]). Objetivos Secundarios: 1. Demostrar en mayor medida la eficacia de la PRRT con lutecio (177Lu) edotreotida. 2. Evaluar el efecto de la PRRT con lutecio (177Lu) edotreotida sobre la calidad de vida relacionada con la salud (CDVRS) de los pacientes y los síntomas del tumor neuroendocrino funcional durante el tratamiento y después de este, en comparación con el tratamiento de referencia. 3. Evaluar la seguridad y la tolerabilidad de la PRRT con lutecio (177Lu) edotreotida en los pacientes del estudio, en comparación con las opciones terapéuticas de control.

Documentos

No hay documentos

Participantes

María Isabel Del Olmo García

Investigador Colaborador
Irene Torres Espallardo

Investigador Colaborador
Pilar Bello Arques

Investigador Colaborador
Judith Pérez Rojas

Investigador Colaborador
José Luis Poveda Andrés

Investigador Colaborador
Maite Giralt Ferrer

Data Manager / Study Coordinator
Ángel Agustín Segura Huerta

Investigador Principal
Stephan Guillermo Prado Wohlwend

Investigador Colaborador
Maria Perez Fernandez

Técnico Apoyo Investigación
Jose Fernando Melo Villamarin

Investigador Colaborador
Dayana Michelle Pita Endara

Investigador Colaborador
Sonia Gines Cardenas

Investigador Colaborador
Africa Almendros Riaza

Investigador Colaborador
Fatima Tomas Medina

Investigador Colaborador
Oussama Bardouz Gouguasse

Investigador Colaborador
Silvia Maestro Huguet

Investigador Colaborador
Maria Del Mar San Juan Tubilleja

Investigador Colaborador
Elena Teijeiro Vazquez

Investigador Colaborador

Ver todos los Investigadores

Grupos

Investigación Clínica y Traslacional en Cáncer

Leader

José Gómez Codina
Hepatología, Cirugia Hepatobiliopancreática y Trasplantes

Leader

Marina Berenguer Haym
Farmacogenética

Investigador Principal

María José Herrero Cervera
Investigacion Biomédica en Imagen (GIBI 2-30)

Investigador Principal

Leonor Cerdá Alberich
Unidad Mixta de Investigación en Endocrinología, Nutrición y Dietética clínica

Leader

Juan Francisco Merino Torres
Núcleo de investigación traslacional integrado Urológico de Valencia (NITIUV)

Leader

César David Vera Donoso
Unidad de Descubrimiento de Fármacos (UDF)

Investigador Principal

Leonor Puchades Carrasco
Grupo de Investigación de Farmacia

Investigador Principal

Javier García Pellicer

Financiadores - Promotores

ITM Solucin GmbH

Resultados del Ensayo Clínico

Publicaciones en Revistas 150

[ 177 Lu]Lu-DOTA-TATE and [ 131 I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center.

Prado-Wohlwend, Stefan; (...); Merino-Torres, Juan Francisco

Article. 10.3389/fendo.2022.778322. 2022

[[Tranaslated article]]Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years.

López DF; (...); Ortiz-Romero, P. L.

Article. 10.1016/j.ad.2022.11.013. 2023

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025

[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.

Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.09.006. 2024

177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors

Jimenez-Fonseca, P.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2022

177-Lu-DOTATATE in 382 patients with somatostatin receptor-positive advanced tumors: Real-world data from the SEPTRALU registry

Casanovas M, Mitjavila; (...); Carmona-Bayonas, A.

Meeting Abstract. 2022

177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations - Data from 552 cases in the SEPTRALU registry

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2023

A Gadolinium(III) Complex Based on Pyridoxine Molecule with Single-Ion Magnet and Magnetic Resonance Imaging Properties.

Orts-Arroyo, Marta; (...); Martinez-Lillo, Jose

Article. 10.3390/ijms25042112. 2024

A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022

Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022

Comparing the direct assessment of steatosis in liver explants with mid- and near-infrared vibrational spectroscopy, prior to organ transplantation.

Rienda, Ivan; (...); Quintas, Guillermo

Article. 10.1039/d3an01184d. 2023

Comparison of 3D dosimetry methods in hepatic radioembolisation with Y-90 microspheres

Carrasco Vela, N.; (...); Torres-Espallardo, I.

Meeting Abstract. 2021

Comparison of protocols with respiratory-gated (4D) motion compensation in PET/CT: open-source package for quantification of phantom image quality.

Martinez-Movilla, Andrea; (...); Carles, Montserrat

Article. 10.1186/s40658-022-00509-4. 2022

Comparison of psychological distress for breast, ovarian and colorectal cancer predisposition in a Spanish sample at high risk of hereditary cancer.

Costa-Requena, Gema; (...); Segura-Huerta, Angel

Article. 10.1097/CEJ.0000000000000734. 2022

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023

Correlation Between Clinical Characteristics And Effective Washout Time In Patients Treated With High Radioiodine Activities

Guerrero Calatayud, C.; (...); Bello Arques, P.

Meeting Abstract. 2023

Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021

Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024

Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024

Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score

Marti-Aguado, David; (...); Marti-Bonmati, Luis

Article. 10.1111/liv.15766. 2024

Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease.

Marti-Aguado, David; (...); Marti-Bonmati, Luis

Article. 10.3390/biom11121808. 2021

Do SPECT CT and sentinel node tecnhique increase the diagnosis of metastasic disease in prostate cancer?

Perez Ardavin, J.; (...); Vera-Donoso, C. D.

Meeting Abstract. 2022

Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.

Lopez-Pascual, Ernesto; (...); Castell, Jose V.

Article. 10.3390/ijms25105203. 2024

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.

Capdevila, J.; (...); Manzano, J. L.

Article. 10.1038/s41467-023-38611-5. 2023

Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A multicenter study

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2023

Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study.

Mitjavila, Mercedes; (...); Carmona-Bayonas, Alberto

Article. 10.1007/s00259-023-06166-8. 2023

Enhancing the accuracy of mid-infrared spectroscopy-based liver steatosis quantification using digital image analysis as a reference.

Rienda, Ivan; (...); Quintas, Guillermo

Article. 10.1039/d3an00324h. 2023

Evaluation of 177Lu-DOTATATE treatment in patients with metastasic or unresectable paragangliomas and pheochromocytomas

Canon Sanchez, J.; (...); Utrera Costero, A.

Meeting Abstract. 2021

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

Vera, Ruth; (...); Madrigal-Rubiales, Beatriz

Article. 10.1007/s12094-022-02873-0. 2022

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.

Vera, Ruth; (...); Madrigal-Rubiales, Beatriz

Article. 10.1016/j.patol.2022.06.004. 2023

Fibrillary glomerulonephritis: more frequent than it seems? The diagnostical importance of immunohistochemistry.

Viejo-Boyano I; (...); Hernández-Jaras J

Letter. 10.1016/j.nefroe.2023.05.022. 2024

FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis

Martinez-Arenas, Laura; (...); Berenguer, Marina

Meeting Abstract. 2024

FibroScan compared to liver biopsy for accurately staging recurrent hepatic steatosis and fibrosis after transplantation for MASH.

Martinez-Arenas, Laura; (...); Berenguer, Marina

Article. 10.1111/liv.16085. 2024

Free automatic software for quality assurance of computed tomography calibration, edges and radiomics metrics reproducibility.

Saborido-Moral, Juan D.; (...); Carles, Montserrat

Article. 10.1016/j.ejmp.2023.103153. 2023

Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients.

Perez-Rubio, Alvaro; (...); Jover, Ramiro

Article. 10.3390/nu15143187. 2023

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

Hepatic nerve endings are rewired by cholestatic injury to connect inflamed lymphatics to sites of ductular remodelling

Noon, Luke; (...); Lloyd, Alison

Meeting Abstract. 2023

HepatoPredict Accurately Selects Hepatocellular Carcinoma Patients for Liver Transplantation Regardless of Tumor Heterogeneity

Andrade, Rita; (...); Cardoso, Joana

Article. 10.3390/cancers17030500. 2025

Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives.

Hernandez-Rienda, Lorena, Del Olmo-García MI, Merino-Torres JF

Article. 10.3390/metabo12111103. 2022

Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study

Del Olmo-Garcia, M.; (...); Argente Pla, M.

Meeting Abstract. 2024

Initial Clinical and Treatment Patterns of Advanced Differentiated Thyroid Cancer. ERUDIT Study.

Vallejo Casas, Juan Antonio; (...); Orcajo-Rincon, Lorenzo

Article. 10.1530/ETJ-21-0111. 2022

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024

Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024

Just a matter of weight? Final results from NUTRIGETNE study in patients with Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

Pla, Argente M.; (...); Del Olmo-Garcia, M.

Meeting Abstract. 2024

Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

Alonso-Gordoa, T.; (...); de La Cruz, G.

Meeting Abstract. 2022

Less is more: Usefulness of the sentinel node technique in radical prostatectomy

Perez Ardavin, J.; (...); Vera-Donoso, C. D.

Meeting Abstract. 2022

LIPID DROPLET MORPHOLOGY JUSTIFIES DISCORDANCES BETWEEN HEPATIC STEATOSIS GRADES AND MRI PROTON DENSITY FAT FRACTION

Marti-Aguado, David; (...); Marti-Bonmati, Luis

Meeting Abstract. 2024

Lu-177-DOTATATE therapy in advanced pancreatic neuroendocrine tumors: data from 187 patients of the national registry SEPTRALU

Mitjavila-Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2022

Lutetium177 in patients with stage IV neuroendocrine tumours of any origin. Data from 321 patients of the multicenter national registry

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2021

MAGNETIC RESONANCE IMAGING-BASED BIOMARKER ACCURATELY IDENTIFIES PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND CLINICALLY SIGNIFICANT LIVER FIBROSIS: A MULTICENTER, INTERNATIONAL, VALIDATION STUDY

Arnouk, Joud; (...); Marti-Bonmati, Luis

Meeting Abstract. 2021

Magnetic resonance imaging-based biomarker accurately identifies patients with nonalcoholic steatohepatitis and significant liver fibrosis: a multicentre, international, validation study

Marti-Aguado, David; (...); Marti-Bonmati, Luis

Meeting Abstract. 2022

MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma.

Monteagudo M; (...); Robledo M

Article. 10.1016/j.beem.2024.101931. 2024

Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy.

Muñoz de Nova JL; (...); Martin-Perez, Elena

Review. 10.3748/wjg.v28.i13.1304. 2022

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022

Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

Nutritional status of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain - NUTRIGETNE study

Hernandez-Rienda, L.; (...); Del Olmo-Garcia, M.

Meeting Abstract. 2023

Objective Image Quality Comparison Between Brain-Dedicated PET and PET/CT Scanners.

Gandia-Ferrero MT; (...); Martí-Bonmatí L

Article. 10.1007/s10916-023-01984-7. 2023

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023

Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023

OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024

Pancreatic cancer, Radiomics and Artificial Intelligence: A Review.

Marti-Bonmati L; (...); Alberich-Bayarri A

Article. 10.1259/bjr.20220072. 2022

Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease.

Marti-Aguado D; (...); Marti-Bonmati L

Article. 10.3389/fendo.2023.1213441. 2023

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

del Olmo-Garcia, Maria I.; (...); Merino-Torres, Juan F.

Article. 10.3390/cancers14030584. 2022

Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.

Ortuzar, Ariana; (...); Osorio, Santiago

Article. 10.1007/s00277-022-05044-x. 2022

Polyribonucleotide phosphorylase is overexpressed in hepatocellular cancer, promoting epithelial phenotype maintenance and tumor progression

Revert-Ros, Francisco; (...); Hernandez-Andreu, Jose Miguel

Article. 10.1016/j.prp.2024.155713. 2024

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy

Capdevila J; (...); Pubul V

Article. 10.1093/oncolo/oyab041. 2022

Prediction of patient progression-free survival with ¹⁷⁷Lu-DOTATATE in clinical practice: NEPTUNESEPTRALU model for patient selection

Mitjavila Casanovas, M.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2024

Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years.

Falkenhain-Lopez, D; (...); Ortiz-Romero, P L

Article. 10.1016/j.ad.2022.11.010. 2023

Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) - Data from the national registry SEPTRALU

Bello, P.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2023

Prognosticating hepatocellular carcinoma before and after liver transplantation with HepatoPredict

Silva, Silvia Gomes; (...); Cardoso, Joana

Meeting Abstract. 2024

Progress and challenges of mid-infrared spectroscopy for liver characterization focusing on steatosis, fibrosis and cancer

Ten-Domenech, Isabel; (...); Quintas, Guillermo

Review. 10.1080/05704928.2023.2215858. 2024

Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat

Quintas, Guillermo; (...); Jover, Ramiro

Article. 10.3390/ijms23169298. 2022

Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review.

Prado-Wohlwend, Stefan; (...); Merino-Torres JF

Article. 10.3389/fendo.2022.957172. 2022

Retreatment PRRT with 177Lu-DOTATATE in patients with progressive neuroendocrine neoplasm: Spanish clinical experience from national registry

Mitjavila Casanovas, M.; (...); Hernando, J.

Meeting Abstract. 2024

Same-day comparative protocol PET/CT-PET/MRI [68Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine.

Prado-Wohlwend, Stefan; (...); Merino-Torres, Juan Francisco

Article. 10.1186/s40644-023-00521-6. 2023

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).

Castillón JC; (...); Plazas JG

Article. 10.1007/s12094-023-03205-6. 2023

Sequential treatment of High-risk Neuroblastoma combining I-131 MIBG high-dose and Topotecan. First experience

Orrego, N.; (...); Bello-Arques, P.

Meeting Abstract. 2023

Sinusoidal Obstruction Syndrome after Liver Transplantation: A Multicenter Observational Study.

Caballero-Marcos A; (...); Salcedo M

Article. 10.1002/lt.26452. 2022

SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022

The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis

Soluyanova, Polina; (...); Jover, Ramiro

Article. 10.3390/biom14111423. 2024

The NETFIT trial: Smart wearable medical devices to assess the quality of life of patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Molina Cerrillomd, Javier; (...); Capdevila, Jaume

Meeting Abstract. 2023

The Potential Role of Efficacy and Safety Evaluation of N-Acetylcysteine Administration During Liver Procurement. The NAC-400 Single Center Randomized Controlled Trial

Gomez-Gavara, C; (...); Lopez-Andujar, R

Article. 10.1097/TP.0000000000003487. 2021

The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024

Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024

Uncovering the genomic profiling of metastatic pheochromocytomas and paragangliomas: Leveraging plasma circulating tumor DNA for comprehensive genetic characterisation and monitoring

Arenillas, Lallana C.; (...); Toledo, R. A.

Meeting Abstract. 2024

Update on iodine-refractory differentiated thyroid carcinoma

Casas, E. Abou Jokh; (...); Casas, J. A. Vallejo

Article. 10.1016/j.remn.2023.06.005. 2023

Update on iodine-refractory differentiated thyroid carcinoma.

Jokh Casas, E A; (...); Vallejo Casas, J A

Article. 10.1016/j.remnie.2023.07.003. 2023

VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA

Poveda, J. L.; (...); Lizan, L.

Meeting Abstract. 2023

Y-90 PET/MR imaging optimization with a Bayesian penalized likelihood reconstruction algorithm.

Calatayud-Jordan, Jose; (...); Torres-Espallardo, Irene

Article. 10.1007/s13246-024-01452-7. 2024